Home Page
Better Biologics - Galixa™
precision-engineered glycosylation technology for safer, more effective biologics.
“Galixa™ is our plug-and-play precision glycoengineering technology hardwired into the cell line to enable more consistent glycan profiles, supporting improved therapeutic function, stability, manufacturability and reduced production of detrimental high mannose in biologics development.”
A UCD Spin-off
Enterprise Ireland Backed
PCT/EP2021/072287 Filed
UCD Exclusive Licence
2-Step
Plug & play cell engineering
3x
Increase in galactosylation (addition of sugars)
4x
Reduction in manufacturing variability
Multi-x
Multi-factorial product enhancement*
*Optimizes Antibody Function, Enhances Drug Stability, Reduces Immunogenicity, Controls Clinical Profile – Pharmacokinetics & Pharmacodynamics
Exclusivity
Galixa™ derived biologics are eligible for new composition of matter protection
For Investors
The antibody industry already pays billions for enhanced effector function. GalixaTM is a technology platform – not a single drug.
Validated Technology
From distinguished UCD lab, data in multiple CHO cell lines
Industry Tailwind
mAb patent cliff, biosimilar wave and the ADC boom
Proven Path to Exit
The strategic acquirer playbook for this exact technology exists
The Ask
Raising seed round
For Industry
Galactosylation, hardwired using a two-step engineering of the CHO host cell that locks in consistently high galactosylation – permanently, at the source
Engineer the Host
Reduce upstream process development burden
Hardwire consistency
Ensuring scalability and reproducibility
Enhance Therapeutic
Multi-factor product profile enhancement
Feasibility License
Low-hurdle access to generate first-hand data